Literature DB >> 26845449

Tumor microenvironment and therapeutic response.

Ting Wu1, Yun Dai2.   

Abstract

The tumor microenvironment significantly influences therapeutic response and clinical outcome. Microenvironment-mediated drug resistance can be induced by soluble factors secreted by tumor or stromal cells. The adhesion of tumor cells to stromal fibroblasts or to components of the extracellular matrix can also blunt therapeutic response. Microenvironment-targeted therapy strategies include inhibition of the extracellular ligand-receptor interactions and downstream pathways. Immune cells can both improve and obstruct therapeutic efficacy and may vary in their activation status within the tumor microenvironment; thus, re-programme of the immune response would be substantially more beneficial. The development of rational drug combinations that can simultaneously target tumor cells and the microenvironment may represent a solution to overcome therapeutic resistance.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Microenvironment; Resistance; Target therapy

Mesh:

Substances:

Year:  2016        PMID: 26845449     DOI: 10.1016/j.canlet.2016.01.043

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  416 in total

1.  PLK1: a promising and previously unexplored target in double-hit lymphoma.

Authors:  Quais N Hassan; Lapo Alinari; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

2.  Comprehensive Computed Tomography Radiomics Analysis of Lung Adenocarcinoma for Prognostication.

Authors:  Geewon Lee; Hyunjin Park; Insuk Sohn; Seung-Hak Lee; So Hee Song; Hyeseung Kim; Kyung Soo Lee; Young Mog Shim; Ho Yun Lee
Journal:  Oncologist       Date:  2018-04-05

Review 3.  Complex interplay between tumor microenvironment and cancer therapy.

Authors:  Minhong Shen; Yibin Kang
Journal:  Front Med       Date:  2018-08-10       Impact factor: 4.592

4.  High density of CD66b in primary high-grade ovarian cancer independently predicts response to chemotherapy.

Authors:  Alberto Posabella; Philipp Köhn; Alexandros Lalos; Alexander Wilhelm; Robert Mechera; Savas Soysal; Simone Muenst; Uwe Güth; Sylvia Stadlmann; Luigi Terracciano; Raoul A Droeser; Jasmin Zeindler; Gad Singer
Journal:  J Cancer Res Clin Oncol       Date:  2019-12-18       Impact factor: 4.553

5.  Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.

Authors:  Tongtong Wei; Jinjing Song; Kai Liang; Li Li; Xiaoxiang Mo; Zhiguang Huang; Gang Chen; Naiquan Mao; Jie Yang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

Review 6.  Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy.

Authors:  Meng Lan; Wenping Lu; Tengteng Zou; Lihong Li; Fengjie Liu; Tiange Cai; Yu Cai
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

7.  Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.

Authors:  Yi Liao; Dingxiu He; Fuqiang Wen
Journal:  Immunogenetics       Date:  2021-07-24       Impact factor: 2.846

8.  Identification of a tumor microenvironment-associated prognostic gene signature in bladder cancer by integrated bioinformatic analysis.

Authors:  Zhengchun Liu; Xiuli Liu; Rui Cai; Meilian Liu; Rensheng Wang
Journal:  Int J Clin Exp Pathol       Date:  2021-05-15

Review 9.  Research on CRISPR/system in major cancers and its potential in cancer treatments.

Authors:  Z Liu; Z Liao; Y Chen; L Zhou; W Huangting; H Xiao
Journal:  Clin Transl Oncol       Date:  2020-07-15       Impact factor: 3.405

10.  Real-time, high-resolution imaging of tumor cells in genetically engineered and orthotopic models of thyroid cancer.

Authors:  Xhesika Shanja-Grabarz; Anouchka Coste; David Entenberg; Antonio Di Cristofano
Journal:  Endocr Relat Cancer       Date:  2020-10       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.